Synergistic Effect of Aβ42 and Tau Protein in Alzheimer's Disease
Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v5i3.2764
Abstract
Alzheimer's disease (AD) is a neurodegenerative disease that can't be cured at present, which is different from what we call infectious diseases, and is usually related to senile dementia. Although there is no radical cure at present, early diagnosis and intervention can delay the progress of the disease and improve the quality of life of patients. The mechanism of Aβ42 and Tau protein in AD is of great significance for early diagnosis and treatment of diseases. In this paper, the interaction between these two proteins is deeply analyzed, and their role in the pathological development of AD is discussed, and how to use this knowledge to improve the accuracy of clinical diagnosis and develop new treatment strategies.
Keywords
Alzheimer's disease; Aβ42; Tau protein; Synergy; clinical diagnosis introduction
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] Yan Shengyun, Li Yinan, Ma Yun, et al. Research on the design of family service system for Alzheimer's disease based on KANO-AHP [J/OL]. Packaging Engineering, 1-13[2024-06-11].
[2] Cao Renyi. Experimental study on digital interactive device for Alzheimer's disease from the perspective of AR [J]. Footwear Technology and Design, 2024,4(08):114-116.
[3] Bao Li, Pan Hui, Ji Meng, et al. Current situation and challenges of neural stem/progenitor cells in the treatment of Alzheimer's disease [J/OL]. china biotechnology, 1-24 [June-November, 2024].
[4] Chen Long, Zhou Ning, Wang Ruifeng, et al. Study on the intervention of adenosine on Alzheimer's disease based on non-targeted metabonomics [J]. Journal of Pharmacy, China Hospital, 2024,44(09):1007-1015.
[5] Hu Jianju, Zhang Xiaolong, Zeng Yan, et al. Classification of Alzheimer's disease based on population characteristics [J]. Computer and Digital Engineering, 2024,52(02):321-326+331.
[6] Luo S,Wang Y,Hisatsune T. P2Y1 receptor in Alzheimer's disease. [J]. Neural regeneration research, 2025, 20 (2): 440-453.
[7] Sirkis W D,Solsberg W C,Johnson P T, et al. Expansion of highly interferon-responsive T cells in early-onset Alzheimer's disease. [J]. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024,
[8] Venkatesan D,Muthukumar S,Iyer M, et al. Heavy metals toxicity on epigenetic modifications in the pathogenesis of Alzheimer's disease (AD). [J]. Journal of biochemical and molecular toxicology, 2024, 38 (6): e23741-e23741.
[9] Wang J H,Meyyappan C A,Feldman J O, et al. Emerging therapies for treatment of agitation, psychosis, or apathy in Alzheimer's disease. [J]. Expert opinion on emerging drugs, 2024.
[10] Chen J,Rao J,Lu H, et al. Network pharmacology and experimental verification to explore the effect of Hedyotis diffusa on Alzheimer's disease. [J].Chemical biology & drug design,2024,103(6): e14558-e14558.
[2] Cao Renyi. Experimental study on digital interactive device for Alzheimer's disease from the perspective of AR [J]. Footwear Technology and Design, 2024,4(08):114-116.
[3] Bao Li, Pan Hui, Ji Meng, et al. Current situation and challenges of neural stem/progenitor cells in the treatment of Alzheimer's disease [J/OL]. china biotechnology, 1-24 [June-November, 2024].
[4] Chen Long, Zhou Ning, Wang Ruifeng, et al. Study on the intervention of adenosine on Alzheimer's disease based on non-targeted metabonomics [J]. Journal of Pharmacy, China Hospital, 2024,44(09):1007-1015.
[5] Hu Jianju, Zhang Xiaolong, Zeng Yan, et al. Classification of Alzheimer's disease based on population characteristics [J]. Computer and Digital Engineering, 2024,52(02):321-326+331.
[6] Luo S,Wang Y,Hisatsune T. P2Y1 receptor in Alzheimer's disease. [J]. Neural regeneration research, 2025, 20 (2): 440-453.
[7] Sirkis W D,Solsberg W C,Johnson P T, et al. Expansion of highly interferon-responsive T cells in early-onset Alzheimer's disease. [J]. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024,
[8] Venkatesan D,Muthukumar S,Iyer M, et al. Heavy metals toxicity on epigenetic modifications in the pathogenesis of Alzheimer's disease (AD). [J]. Journal of biochemical and molecular toxicology, 2024, 38 (6): e23741-e23741.
[9] Wang J H,Meyyappan C A,Feldman J O, et al. Emerging therapies for treatment of agitation, psychosis, or apathy in Alzheimer's disease. [J]. Expert opinion on emerging drugs, 2024.
[10] Chen J,Rao J,Lu H, et al. Network pharmacology and experimental verification to explore the effect of Hedyotis diffusa on Alzheimer's disease. [J].Chemical biology & drug design,2024,103(6): e14558-e14558.
Copyright © 2024 Ruihai Zhu
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License